235 related articles for article (PubMed ID: 20463571)
1. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
[TBL] [Abstract][Full Text] [Related]
2. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
[TBL] [Abstract][Full Text] [Related]
3. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
4. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system.
Carney EM; Banerjee P; Ellis CL; Albadine R; Sharma R; Chaux AM; Burger PC; Netto GJ
Am J Surg Pathol; 2011 Feb; 35(2):262-7. PubMed ID: 21263247
[TBL] [Abstract][Full Text] [Related]
5. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.
Chang A; Brimo F; Montgomery EA; Epstein JI
Hum Pathol; 2013 Aug; 44(8):1563-8. PubMed ID: 23453625
[TBL] [Abstract][Full Text] [Related]
6. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies.
Tuna B; Unlu M; Aslan G; Secil M; Yorukoglu K
Anal Quant Cytol Histol; 2009 Apr; 31(2):118-22. PubMed ID: 19402389
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical markers for the differential diagnosis of nephrogenic adenomas.
Quinones W; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Feb; 17(1):41-4. PubMed ID: 22672805
[TBL] [Abstract][Full Text] [Related]
9. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
[TBL] [Abstract][Full Text] [Related]
10. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma.
Gailey MP; Bellizzi AM
Am J Clin Pathol; 2013 Dec; 140(6):872-80. PubMed ID: 24225756
[TBL] [Abstract][Full Text] [Related]
12. Primary carcinoma of renal calyx.
Williams PA; Mai KT
Pathol Res Pract; 2013 Oct; 209(10):654-61. PubMed ID: 23999038
[TBL] [Abstract][Full Text] [Related]
13. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.
Langner C; Ratschek M; Tsybrovskyy O; Schips L; Zigeuner R
J Histochem Cytochem; 2003 Aug; 51(8):1097-9. PubMed ID: 12871991
[TBL] [Abstract][Full Text] [Related]
14. PAX8 expression in sporadic hemangioblastoma of the kidney supports a primary renal cell lineage: implications for differential diagnosis.
Zhao M; Williamson SR; Yu J; Xia W; Li C; Zheng J; Zhu Y; Sun K; Wang Z; Cheng L
Hum Pathol; 2013 Oct; 44(10):2247-55. PubMed ID: 23849894
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
16. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study.
Tong GX; Yu WM; Beaubier NT; Weeden EM; Hamele-Bena D; Mansukhani MM; O'Toole KM
Mod Pathol; 2009 Sep; 22(9):1218-27. PubMed ID: 19525927
[TBL] [Abstract][Full Text] [Related]
17. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.
Clayton EF; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Apr; 17(2):192-7. PubMed ID: 23218904
[TBL] [Abstract][Full Text] [Related]
18. High-grade carcinomas involving the renal sinus: report of a case and review of the differential diagnosis and immunohistochemical expression.
Young A; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):907-10. PubMed ID: 22849739
[TBL] [Abstract][Full Text] [Related]
19. Protein gene product 9.5 is diagnostically helpful in delineating high-grade renal cell cancer involving the renal medullary/sinus region from invasive urothelial cell carcinoma of the renal pelvis.
Gunia S; Erbersdobler A; Koch S; Otto W; Staibano S; D'Alterio C; Brookman-May S
Hum Pathol; 2013 May; 44(5):712-7. PubMed ID: 23158209
[TBL] [Abstract][Full Text] [Related]
20. Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.
Knoepp SM; Kunju LP; Roh MH
Diagn Cytopathol; 2012 Aug; 40(8):667-72. PubMed ID: 22807381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
